Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan CED in Recurrent IDH-Mutant Malignant Glioma
NCT06666712Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of topotecan in malignant glioma. Primary endpoint: Safety (Dose with <= Grade 2 Adverse Reactions) up to 29 days. Started Jun 2026; status: recruiting.
02
Drugs
topotecan
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT06666712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666712.